View all news

Masimo Launches Enhanced Masimo Patient SafetyNet(TM) System to Help Hospitals Reduce Preventable Deaths on the General Floor

09/15/2009
New Features Expand Monitoring Capabilities, Simplify Operation and Extend Capabilities to Cover Up to 80 Patients Per Server on Up to Four Floors

IRVINE, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, today introduced a new enhanced version of the Masimo Patient SafetyNet system designed to help hospitals avoid preventable patient deaths and injuries associated with failure to rescue - one of today's most common medical errors.(1) New features such as an intuitive touch-screen interface and the ability to monitor up to 80 patients simultaneously on four separate floors allow hospitals to noninvasively and remotely monitor more patients, in more care areas, more efficiently, and in more clinical detail - enabling an enhanced level of patient safety when a clinician can't be at the bedside.

The Masimo Patient SafetyNet remote monitoring and clinician notification system combines the gold standard performance of Masimo SET((R)) pulse oximetry with optional Oridion Microstream((R)) end tidal CO2-based respiration rate monitoring at the point of care and wireless clinician notification via pager to provide an unmatched level of patient safety on general care floors. The system uses IEEE industry standards for connectivity - allowing for more efficient sharing of data across a hospital's IT platforms and the option of full integration into a hospital's existing IT infrastructure, providing a lower overall cost of ownership and improved financial benefits.

One of the most common dangers in hospitals today is the risk of death or serious injury caused by medications designed to relieve pain and help keep patients comfortable. Growing concerns over the use of patient-controlled analgesia (PCA) in the post-operative period have caused leading patient safety organizations to institute new recommendations and guidelines to combat the "unexpected and potentially harmful opioid-induced respiratory depression that continues to occur." According to the latest direction from the Anesthesia Patient Safety Foundation (APSF), these dangers exist because "in most cases, there is inadequate monitoring of oxygenation and/or ventilation." The APSF further warns hospital clinicians that "intermittent subjective assessments of ventilation or level of consciousness are unreliable predictors of future respiratory depression, even over short time frames" and continuous monitoring of oxygenation via pulse oximetry must be "the routine and not the exception."(2)

The new Patient SafetyNet system is already having a big impact on both nurses and post-surgical patients for two hospitals involved in limited market release testing. Marilyn Nemerever, R.N., director of Acute Care at Swedish Medical Center in Seattle, where the new system is being used to monitor patients in three separate post-surgical units at three different hospitals from a single central monitoring station, stated, "We love it. ICU beds are in high demand these days and Patient SafetyNet allows us to more closely monitor post-surgical patients in our med-surg units, so we can use our ICU resources more appropriately. Our nurses now have the piece of mind that comes with knowing that Patient SafetyNet is helping watch over their patients if and when they cannot. And our patients are having better outcomes because we can see, as well as respond to changes earlier."

Clinicians at Dartmouth-Hitchcock Medical Center, who found that Patient SafetyNet reduced rescue activations by 65% and ICU transfers by 48% - while in some patients where ICU transfer was avoided, length of stay was also reduced from 5.8 to 3.6 days with an associated cost of care reduction of 30%, have also embraced the capabilities of the new Patient SafetyNet system. ( )George T. Blike, M.D., Medical Director of Patient Safety at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, stated; "The new system enhancements allow us to see real-time numerics for each patient at a glance, while the ability to monitor more patients on a single server will enable us to deploy the system across more care areas than before to reduce overall costs of implementation."

Another significant risk that post-surgical patients face is undetected internal bleeding. The Patient SafetyNet system can also be easily upgraded to Masimo Rainbow SET Pulse CO-Oximetry technology through a simple software upgrade - allowing hospitals to measure a patient's hemoglobin noninvasively and continuously, which may improve patient safety by providing an earlier indication of undetected internal bleeding and enabling immediate intervention.

Masimo Executive Vice President of Medical Affairs, Michael O'Reilly, MD, stated, "Each year

healthy patients admitted for routine procedures become failure to rescue statistics because an adverse event was not recognized in time to save them. The new capabilities in Masimo Patient SafetyNet significantly expand the functionality of a system that has already been proven to help clinicians improve patient outcomes and decrease costs - two things every hospital wants and needs."

(1) "The Sixth Annual HealthGrades Patient Safety in American Hospitals Study" April 2009. http://www.healthgrades.com/media/DMS/pdf/PatientSafetyInAmericanHospitals Study2009.pdf

(2) "Dangers of Postoperative Opioids--Is there a Cure?" APSF Newsletter: The Official Journal of the Anesthesia Patient Safety Foundation. Summer 2009; Volume 24, No. 2, 25-32. http://www.healthgrades.com/media/DMS/pdf/PatientSafetyInAmericanHospitals Study2009.pdf

(3) Dartmouth-Hitchcock Medical Center Clinical Abstract Presented at the Society for Technology in Anesthesia (STA) Annual Meeting in San Antonio, Texas on January 15, 2009.

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care - helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET((R)), which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET((R)) Pulse CO-Oximetry(TM), a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO((R))), methemoglobin (SpMet((R))), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.

Forward Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that Masimo Patient SafetyNet will provide an effective early warning system of a patient's deteriorating physiological condition to enable timely rescue, risks related to our belief that Masimo Rainbow SET Pulse CO-Oximetry measurements and Masimo Desat Index 3D Alarms will provide sufficient sensitivity and specificity to detect physiological abnormalities and potentially life-threatening conditions in real-time for all patients, risks related to our assumptions regarding the repeatability of Swedish Medical Center and/or Dartmouth-Hitchcock Medical Center clinical results, and risks related to our assumptions regarding the systems' ability to deliver clinical improvement over alternative patient monitoring and assessment methods to increase patient safety and allow for further adoption of the technology, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Media Contact:
Dana Banks,
Masimo Corporation
949-297-7348

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.

SOURCE Masimo

Multimedia Files:

Categories: Press Releases
View all news